The effect that marketing has had on the prescription decisions of the medical profession is an area of great social and governmental concern and has been the subject of substantial international debate. In this study, the importance of brand name as a factor influencing the prescription habits of general practitioners and psychiatrists is examined. Data on antidepressant prescriptions supplied by the Australian Governments Pharmaceutical Benefit Scheme and results derived from MANOVA and ANOVA analyses suggest that the brand name as much as chemical differences influenced the prescription of choice of antidepressants by both general practitioners and psychiatrists. The use of a well-promoted brand name may be an important evaluation shortcut by both groups regardless of detailed training resulting in medical practices, which may undermine the social imperative of affordable medical care for all. The authors suggest that clinical appropriateness of prescriptions for antidepressants by brand name needs further investigation.
Aaker, J., and D. Maheswaran.1997. The effect of cultural orientation and cue diagnosticity on processing and product evaluations. Journal of Consumer Research24 (December): 315-27.
2.
Alba, J., and W. Hutchinson.1987. Dimensions of consumer expertise. Journal of Consumer Research13 (March): 411-54.
3.
Allwood, C.1984. When novices surpass experts: The difficulty of a task may increase with expertise. Psychology, Learning, Memory, and Cognition10:483-95.
4.
Andaleeb, S., and R. Tallman.1996. Relationship of physicians with pharmaceutical sales representatives and pharmaceutical companies. Health Marketing Quarterly13:78-89
5.
Anderson, N.1996. A functional theory of cognition. Mahwah, NJ: Lawrence Erlbaum.
6.
Antonuccio, D., D. Burns, and W. Danton.2002. Antidepressants: A triumph of marketing over science. Prevention and Treatment5 (8): 963-69.
7.
Audhesh, P., S. Kulkarni, and G. Gopal.2003. Loyalty towards the country, the state and the service brands. Journal of Brand Management10 (3): 233-51.
8.
Baker, S., J. Gentry, and T. Rittenburg.2005. Building understanding of the domain of consumer vulnerability. Journal of Macromarketing25 (2): 128-39.
9.
Beardsley, R., G. Gardocki, and D. Larson.1988. Prescribing of psychotropic medication by primary care physicians and psychiatrists. Archives of General Psychiatry45 (December): 1117-19.
10.
Benson, P.1983. Factors associated with antipsychotic drug prescribing by Southern psychiatrists. Medical Care21 (6): 639-54.
11.
Bero, L.2003. Implications of the tobacco industry documents for public health and policy. Annual Review of Public Health24:267-88.
12.
Breen, K.2004. The medical profession and the pharmaceutical industry: When will we open our eyes? Medical Journal of Australia180:409-10.
13.
Brucks, M., V. Zeithaml, and G. Naylor.2000. Price and brand name as indicators of quality dimensions for consumer durables. Academy of Marketing Science Journal28 (3): 359-74.
14.
Cadeaux, J.2000. Market mechanisms and external benefits of consumption . Journal of Macromarketing20 (1): 11-22.
15.
Choe, S., and H. Cho.2000. The effect of knowledge of Asian brands on the purchase decisions of young American consumers on products from China, Japan, and South Korea. Advances in Competitiveness Research15:1-81.
16.
Cobb-Walgren, C., C. Ruble, and N. Donthu.1995. Brand equity, brand preference, and purchase intent. Journal of Advertising24 (September): 25-42.
17.
Commonwealth Department of Health and Aged Care.1999. Health expenditure: Its management and sources. In International approaches to funding health care. Vol. 3. Canberra, Australia: Commonwealth Department of Health and Aged Care.
18.
Department of Health and Ageing.2005. Pharmaceutical benefits scheme. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/Pharmaceutical+Benefits+Scheme+%28PBS%29-3 (accessed December 4, 2005).
19.
Donoghue, J., A. Tylee, and H. Wildgust.1996. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-1995 . British Medical Journal313 (7061): 861-62.
20.
Donohue, J., and E. Berndt.2004. Effects of direct-to-consumer advertising on medication choice: The role of antidepressants. Journal of Public Policy and Marketing23 (2): 115-27.
21.
Druss, B., S. Olfson, and M. Pincus.2004. Listening to generic Prozac: Winners, losers and sideliners. Health Affairs23 (5): 210-16.
22.
Evans, K., and R. Beltramini.1986. Physicians acquisitions of prescription drug information. Journal of Health Care Marketing6:15-25.
23.
Freeman, J., K. Summers, and S. Szeinbach.1993. Modeling physicians' prescribing decisions for patients with panic disorder. Health Care Marketing13 (1): 34-39.
24.
Gigerenzer, G., P. Todd, and ABC Research Group.1999. Simple heuristics that make us smart. New York: Oxford University Press.
25.
Gonul, F., F. Carter, E. Petrova, and K. Srinivasan.2001. Promotion of prescription drugs and its impact on physician's choice behavior. Journal of Marketing65 (3): 79-90.
26.
Hadsall, R., R. Freeman, and J. Norwood.1982. Factors related to the prescribing of selected psychotic drugs by primary care physicians. Social Science Medicine16:1747-56.
27.
Holbrook, M., D. Lehmann, and J. O'Shaughnessy .1983. Using versus choosing: The relationship of the consumption experience to reasons for purchasing. European Journal of Marketing20:49-62.
28.
Holden, C.2000. Global survey examines impact of depression. Science288 (7): 39-40.
29.
Hong, F., A. Pecotich, and C. Shultz.2002. Brand name translation: Language constraints, product attributes, and consumer perceptions in East and Southeast Asia. Journal of International Marketing10 (2): 29-45.
30.
Jacoby, J., V. Johar, and M. Morrin.1998. Consumer behavior: A quadrennium. Annual Review of Psychology49:319-44.
31.
Kahneman, D.,P. Slovic, and A. Tversky, eds. 1982. Judgment under uncertainty: Heuristics and biases. Cambridge , UK: Cambridge University Press.
32.
Kapmeyer, A., C. Meyer, M. Kochen, and W. Himmel.2006. Doctor's strategies in prescribing drugs: The case of mood-modifying medicines. Family Practice-An International Journal23 (November): 73-79.
33.
Keller, K.1993. Conceptualizing, measuring, and managing customer-based brand equity. Journal of Marketing57 (1): 1-22.
34.
---. 1998. Strategic brand management: Building, measuring, and managing brand equity. Upper Saddle River, NJ: Prentice Hall.
35.
Kotabe, M., A. Peloso, and G. Gregory.2005. International marketing: An Asia Pacific focus. Milton, Australia: John Wiley .
36.
Koyanagi, C., S. Forquer, and E. Alfano.2005. Medicaid policies to contain psychiatric drug costs. Health Affairs24 (2): 536-43.
37.
Lee, L.2004. The current state of public health in China. Annual Review of Public Health25:327-39.
38.
Lehmann, D.2006. It's new but is it good? New product development and macromarketing . Journal of Macromarketing26 (1): 8-16.
39.
Lexchin, J., and B. Mintzes.2002. Direct-to-consumer advertising of prescription drugs: The evidence says no. Journal of Public Policy and Marketing21 (2): 194-201.
40.
Li, Fuan, P. Miniard, and M. Barone.2000. The facilitating influence of consumer knowledge on the effectiveness of daily value reference information. Journal of the Academy Marketing Science28 (3): 425-36.
41.
Linden, M., and C. Thiels.2001. Epidemiology of prescriptions for neuroleptic drugs: Tranquilizers rather than antipsychotics. Pharmacopsychiatry34:150-54.
42.
Loken, B.2006. Consumer psychology: Categorization, inferences, affect, and persuasion. Annual Review of Psychology57:453-86.
43.
Maheswaran, D.1994. Country of origin as a stereotype: Effects of consumer expertise and attribute strength on product evaluations. Journal of Consumer Research21 (3): 354-65.
44.
Maheswaran, D., and J. Meyers-Levy.1990. The influence of message framing and issue involvement. Journal of Marketing Research27 (3): 361-67.
45.
Maheswaran, D., and B. Sternthal.1990. The effects of knowledge, motivation, and type of message on ad processing and product judgments. Journal of Consumer Research17 (1): 66-74.
46.
Malhotra, N.2006. Consumer well being and the quality of life: An assessment and directions for future research. Journal of Macromarketing26 (1): 77-80.
47.
Mallabone, M.2001. UN targets prescription pill-popping. West Australian, February 21, 8.
48.
Mehrotra, A., A. Dudley, and H. Luft.2003. What's behind the health expenditure trends? Annual Review of Public Health24:385-412.
49.
Miller, R.1973. Prescribing habits of physicians: A review of studies on prescribing of drugs. Drug Intelligence and Clinical Pharmacy7 (December): 557-64.
50.
Miyazaki, A., D. Grewal, and R. Goodstein.2005. The effect of multiple extrinsic cues on quality perceptions: A matter of consistency. Journal of Consumer Research32 (June): 146-53.
51.
Neter, J., C. Kuter, J. Wasserman, and C. Nachtsheim.1996. Applied linear statistical models. Homewood, IL: Irwin.
52.
Newell, A., and H. Simon.1972. Human problem solving. Englewood Cliffs, NJ: Prentice Hall.
53.
Oldani, M.2004. Thick prescriptions: Toward an interpretation of pharmaceutical sales practices. Medical Anthropology Quarterly18 (3): 325-56.
54.
Olfson, M., S. Marcus, H. Pincus, J. Zito, J. Thompson, and D. Zarin.1998. Antidepressant prescribing practices of outpatient psychiatrists. Archives of General Psychiatry55 (4): 310-16.
55.
Olson, J.1977. Price as an informational cue: Effects on product evaluations . In Consumer and industrial buying behaviour, ed. Arch G. Woodside.New York: North Holland.
56.
O'Malley, K., and M. O'Hanrahan.1982. Drug promotion and the doctor. British Journal of Clinical Pharmacology14:661-66.
57.
Pecotich, A., S. Ward, and S. Yang.2002. Just a spoonful of sugar: Patent brand name effects on the antidepressant prescription habits of psychiatrists and general practitioners. In Macromarketing in the Asia Pacific century: The proceedings of the 27th annual macromarketing conference , ed. Jack Cadeaux and Anthony Pecotich. Sydney, Australia: University of New South Wales.
58.
Phau, I., and V. Stunornnod.2006. Dimensions of consumer knowledge and its impacts on country of origin effects among Australian consumers: A case of fast-consuming product. Journal of Consumer Marketing23 (1): 34-42.
59.
Poor markets, rich rewards: Why drugmakers should do more for developing countries . 2004. The Economist, September 30, 56.
60.
Randolph, W., and K. Viswanath.2004. Lessons learned from public health mass media campaigns: Marketing health in a crowded media world. Annual Review of Public Health25:419-37.
61.
Rao, A., and K. Monroe.1989. The effect of price, brand name, and store name on buyers' perceptions of product quality: An integrative review . Journal of Marketing Research26 (3): 351-57.
62.
Regalado, A.2003. Who gets health care? Rationing in age of rising costs; message in a bottle: To sell pricey drug, Lilly fuels a debate over rationing; it rallies doctors, patients to speak out for Xgris, even as hospitals balk; grant to study ICU "ethics."Wall Street Journal, September 18, Eastern edition, 1.
63.
Richard, O., and L. Van Horn.2003. Persistence in prescriptions of branded drugs. International Journal of Industrial Organization22 (4): 523-40.
64.
Richardson, P., and A. Dick.1994. Extrinsic and intrinsic cue effects on perceptions of store brand quality. Journal of Marketing58 (4): 28-36.
65.
Ringold, D.2005. Vulnerability in the marketplace: Concepts, caveats, and possible solutions. Journal of Macromarketing25 (2): 202-14.
66.
Rodgers, W., P. Mansfield, J. Braunack-Mayer, and J. Jureidini.2004. The ethics of pharmaceutical industry relationships with medical students. Medical Journal of Australia180:411-12.
67.
Shanteau, J.1992. The psychology of experts: An alternative view. In Expertise and decision support, ed. G. Wright and F. Bolger, 11-23. New York: Plenum.
68.
Sleath, B., and T. Shih.2003. Sociological influences on antidepressant prescribing. Social Science and Medicine56 (6): 1335-44.
69.
The 2001, prescription drugs: Protection racket. 2001. The Economist, May 19, 68.
70.
Tylee, A., M. Gapster, J.P. Lepine, and J. Mendelewicz.1999. DEPRES II Depression Research in European Society II: A patient survey of the symptoms, disability and current management of depression in the community. International Clinical Pscyhopharmalogical14:139-51.
71.
Van den Bulte, C., and G. Lilien.2001. Medical innovation revisited: Social contagion versus marketing effort. American Journal of Sociology106 (5): 1409-35.
72.
Vatjanapukka, V., and R. Waryszak.2004. Relationship between consumer knowledge, prescription drug advertising exposure and attitudes towards direct-to-consumer prescription drug advertising. International Journal of Medical Marketing4 (4): 350-60.
73.
Wagner, J., and E. McCarthy.2004. International differences in drug prices . Annual Review of Public Health25:475-95.
74.
Wilke, M.1997. Glaxo pumps $55 million into Zyban DTC push. Advertising Age68 (32): 4-6.
75.
Wilkerson, J.2003. The political economy of health in the United States. Annual Review of Political Science6:327-43.
76.
World Health Organization.2004. World health report: Changing history. Geneva, Switzerland: World Health Organization.
77.
Wright, R., and W. Lundstrom.2004. Physicians' perceptions of pharmaceutical sales representatives: A model for analyzing the customer relationship. International Journal of Medical Marketing4 (1): 29-38.
78.
Zelino, R.1982. The interaction among the criteria physicians use when prescribing. Medical Care20 (3): 277-85.
